A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

Donald C. Goff, Lisa M. Sullivan, Joseph Patrick McEvoy, Jonathan M. Meyer, Henry A. Nasrallah, Gail L. Daumit, Steven Lamberti, Ralph B. D'Agostino, Thomas S. Stroup, Sonia Davis, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

396 Citations (Scopus)

Abstract

Objective: Standardized mortality rates are elevated in schizophrenia compared to the general population. The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics. Method: Ten-year risk for CHD was calculated for 689 subjects who participated in the Clinical Trials of Antipsychotic Treatment Effectiveness (CATIE) Schizophrenia Trial at baseline using the Framingham CHD risk function and were compared with age-, race- and gender-matched controls from the National Health and Nutrition Examination Survey (NHANES) III. Results: Ten-year CHD risk was significantly elevated in male (9.4% vs. 7.0%) and female (6.3% vs. 4.2%) schizophrenia patients compared to controls (p = 0.0001). Schizophrenia patients had significantly higher rates of smoking (68% vs. 35%), diabetes (13% vs. 3%), and hypertension (27% vs. 17%) and lower HDL cholesterol levels (43.7 vs. 49.3 mg/dl) compared to controls (p < 0.001). Only total cholesterol levels did not differ between groups. Ten-year CHD risk remained significantly elevated in schizophrenia patients after controlling for body mass index (p = 0.0001). Conclusions: These results are consistent with recent evidence of increased cardiac mortality in schizophrenia patients. While the impact of cigarette smoking is clear, the relative contributions to cardiac risk of specific antipsychotic agents, diet, exercise, and quality of medical care remain to be clarified.

Original languageEnglish (US)
Pages (from-to)45-53
Number of pages9
JournalSchizophrenia Research
Volume80
Issue number1
DOIs
StatePublished - Dec 1 2005

Fingerprint

Antipsychotic Agents
Schizophrenia
Coronary Disease
Clinical Trials
Mortality
Smoking
Nutrition Surveys
Quality of Health Care
HDL Cholesterol
Body Mass Index
Cholesterol
Exercise
Diet
Hypertension
Incidence
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. / Goff, Donald C.; Sullivan, Lisa M.; McEvoy, Joseph Patrick; Meyer, Jonathan M.; Nasrallah, Henry A.; Daumit, Gail L.; Lamberti, Steven; D'Agostino, Ralph B.; Stroup, Thomas S.; Davis, Sonia; Lieberman, Jeffrey A.

In: Schizophrenia Research, Vol. 80, No. 1, 01.12.2005, p. 45-53.

Research output: Contribution to journalArticle

Goff, DC, Sullivan, LM, McEvoy, JP, Meyer, JM, Nasrallah, HA, Daumit, GL, Lamberti, S, D'Agostino, RB, Stroup, TS, Davis, S & Lieberman, JA 2005, 'A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls', Schizophrenia Research, vol. 80, no. 1, pp. 45-53. https://doi.org/10.1016/j.schres.2005.08.010
Goff, Donald C. ; Sullivan, Lisa M. ; McEvoy, Joseph Patrick ; Meyer, Jonathan M. ; Nasrallah, Henry A. ; Daumit, Gail L. ; Lamberti, Steven ; D'Agostino, Ralph B. ; Stroup, Thomas S. ; Davis, Sonia ; Lieberman, Jeffrey A. / A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. In: Schizophrenia Research. 2005 ; Vol. 80, No. 1. pp. 45-53.
@article{4351f5ef89c34763812186b6df17c8c3,
title = "A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls",
abstract = "Objective: Standardized mortality rates are elevated in schizophrenia compared to the general population. The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics. Method: Ten-year risk for CHD was calculated for 689 subjects who participated in the Clinical Trials of Antipsychotic Treatment Effectiveness (CATIE) Schizophrenia Trial at baseline using the Framingham CHD risk function and were compared with age-, race- and gender-matched controls from the National Health and Nutrition Examination Survey (NHANES) III. Results: Ten-year CHD risk was significantly elevated in male (9.4{\%} vs. 7.0{\%}) and female (6.3{\%} vs. 4.2{\%}) schizophrenia patients compared to controls (p = 0.0001). Schizophrenia patients had significantly higher rates of smoking (68{\%} vs. 35{\%}), diabetes (13{\%} vs. 3{\%}), and hypertension (27{\%} vs. 17{\%}) and lower HDL cholesterol levels (43.7 vs. 49.3 mg/dl) compared to controls (p < 0.001). Only total cholesterol levels did not differ between groups. Ten-year CHD risk remained significantly elevated in schizophrenia patients after controlling for body mass index (p = 0.0001). Conclusions: These results are consistent with recent evidence of increased cardiac mortality in schizophrenia patients. While the impact of cigarette smoking is clear, the relative contributions to cardiac risk of specific antipsychotic agents, diet, exercise, and quality of medical care remain to be clarified.",
author = "Goff, {Donald C.} and Sullivan, {Lisa M.} and McEvoy, {Joseph Patrick} and Meyer, {Jonathan M.} and Nasrallah, {Henry A.} and Daumit, {Gail L.} and Steven Lamberti and D'Agostino, {Ralph B.} and Stroup, {Thomas S.} and Sonia Davis and Lieberman, {Jeffrey A.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/j.schres.2005.08.010",
language = "English (US)",
volume = "80",
pages = "45--53",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

AU - Goff, Donald C.

AU - Sullivan, Lisa M.

AU - McEvoy, Joseph Patrick

AU - Meyer, Jonathan M.

AU - Nasrallah, Henry A.

AU - Daumit, Gail L.

AU - Lamberti, Steven

AU - D'Agostino, Ralph B.

AU - Stroup, Thomas S.

AU - Davis, Sonia

AU - Lieberman, Jeffrey A.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Objective: Standardized mortality rates are elevated in schizophrenia compared to the general population. The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics. Method: Ten-year risk for CHD was calculated for 689 subjects who participated in the Clinical Trials of Antipsychotic Treatment Effectiveness (CATIE) Schizophrenia Trial at baseline using the Framingham CHD risk function and were compared with age-, race- and gender-matched controls from the National Health and Nutrition Examination Survey (NHANES) III. Results: Ten-year CHD risk was significantly elevated in male (9.4% vs. 7.0%) and female (6.3% vs. 4.2%) schizophrenia patients compared to controls (p = 0.0001). Schizophrenia patients had significantly higher rates of smoking (68% vs. 35%), diabetes (13% vs. 3%), and hypertension (27% vs. 17%) and lower HDL cholesterol levels (43.7 vs. 49.3 mg/dl) compared to controls (p < 0.001). Only total cholesterol levels did not differ between groups. Ten-year CHD risk remained significantly elevated in schizophrenia patients after controlling for body mass index (p = 0.0001). Conclusions: These results are consistent with recent evidence of increased cardiac mortality in schizophrenia patients. While the impact of cigarette smoking is clear, the relative contributions to cardiac risk of specific antipsychotic agents, diet, exercise, and quality of medical care remain to be clarified.

AB - Objective: Standardized mortality rates are elevated in schizophrenia compared to the general population. The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics. Method: Ten-year risk for CHD was calculated for 689 subjects who participated in the Clinical Trials of Antipsychotic Treatment Effectiveness (CATIE) Schizophrenia Trial at baseline using the Framingham CHD risk function and were compared with age-, race- and gender-matched controls from the National Health and Nutrition Examination Survey (NHANES) III. Results: Ten-year CHD risk was significantly elevated in male (9.4% vs. 7.0%) and female (6.3% vs. 4.2%) schizophrenia patients compared to controls (p = 0.0001). Schizophrenia patients had significantly higher rates of smoking (68% vs. 35%), diabetes (13% vs. 3%), and hypertension (27% vs. 17%) and lower HDL cholesterol levels (43.7 vs. 49.3 mg/dl) compared to controls (p < 0.001). Only total cholesterol levels did not differ between groups. Ten-year CHD risk remained significantly elevated in schizophrenia patients after controlling for body mass index (p = 0.0001). Conclusions: These results are consistent with recent evidence of increased cardiac mortality in schizophrenia patients. While the impact of cigarette smoking is clear, the relative contributions to cardiac risk of specific antipsychotic agents, diet, exercise, and quality of medical care remain to be clarified.

UR - http://www.scopus.com/inward/record.url?scp=27744581955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744581955&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2005.08.010

DO - 10.1016/j.schres.2005.08.010

M3 - Article

C2 - 16198088

AN - SCOPUS:27744581955

VL - 80

SP - 45

EP - 53

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -